- Home
- IAUX vs CYRX Comparison
IAUX vs CYRX Comparison
Compare IAUX & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- CYRX
- Stock Information
- Founded
- IAUX 2020
- CYRX 1999
- Country
- IAUX United States
- CYRX United States
- Employees
- IAUX N/A
- CYRX N/A
- Industry
- IAUX
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- CYRX Health Care
- Exchange
- IAUX Nasdaq
- CYRX Nasdaq
- Market Cap
- IAUX 507.4M
- CYRX 438.7M
- IPO Year
- IAUX N/A
- CYRX N/A
- Fundamental
- Price
- IAUX $0.93
- CYRX $8.64
- Analyst Decision
- IAUX Buy
- CYRX Strong Buy
- Analyst Count
- IAUX 1
- CYRX 10
- Target Price
- IAUX $1.50
- CYRX $11.70
- AVG Volume (30 Days)
- IAUX 5.6M
- CYRX 524.9K
- Earning Date
- IAUX 11-11-2025
- CYRX 11-06-2025
- Dividend Yield
- IAUX N/A
- CYRX N/A
- EPS Growth
- IAUX N/A
- CYRX N/A
- EPS
- IAUX N/A
- CYRX 1.35
- Revenue
- IAUX $76,622,000.00
- CYRX $237,879,000.00
- Revenue This Year
- IAUX $79.79
- CYRX N/A
- Revenue Next Year
- IAUX $92.04
- CYRX $9.08
- P/E Ratio
- IAUX N/A
- CYRX $6.41
- Revenue Growth
- IAUX 40.21
- CYRX 24.93
- 52 Week Low
- IAUX $0.34
- CYRX $4.58
- 52 Week High
- IAUX $1.26
- CYRX $10.46
- Technical
- Relative Strength Index (RSI)
- IAUX 75.79
- CYRX 47.92
- Support Level
- IAUX $0.85
- CYRX $8.13
- Resistance Level
- IAUX $0.90
- CYRX $10.46
- Average True Range (ATR)
- IAUX 0.04
- CYRX 0.56
- MACD
- IAUX 0.01
- CYRX -0.04
- Stochastic Oscillator
- IAUX 92.97
- CYRX 21.89
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.